Phase 3 First line in NSCLC
Research payments
$472,550
Through program year 2025, $472,550 in research payments was reported against Phase 3 First line in NSCLC, across 51 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $7,000 | 1 |
| 2024 | Research | $454,800 | 49 |
| 2023 | Research | $10,750 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Anthony Lam Tustin, CA Named on 4 payments
- Haiying Cheng Bronx, NY Named on 3 payments
- Viran Holden Monett, MO Named on 3 payments
- Nagashree Seetharamu New Hyde Park, NY Named on 3 payments
- Keith Lerro Wilson, NC Named on 3 payments
- Kamalesh Sankhala Beverly Hills, CA Named on 3 payments
- David Berz Los Angeles, CA Named on 3 payments
- Juan Cuevas Bridgeton, MO Named on 3 payments
- Nashat Gabrail Canton, OH Named on 3 payments
- Ehab Elbahesh Huntsville, AL Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.